000119591 001__ 119591
000119591 005__ 20230519145525.0
000119591 0247_ $$2doi$$a10.3390/pharmaceutics13111824
000119591 0248_ $$2sideral$$a126824
000119591 037__ $$aART-2021-126824
000119591 041__ $$aeng
000119591 100__ $$aBáez-Díaz C.
000119591 245__ $$aIntrapericardial delivery of apa-microcapsules as promising stem cell therapy carriers in an experimental acute myocardial infarction model
000119591 260__ $$c2021
000119591 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119591 5203_ $$aThe administration of cardiosphere-derived cells (CDCs) after acute myocardial infarction (AMI) is very promising. CDC encapsulation in alginate-poly-L-lysine-alginate (APA) could increase cell survival and adherence. The intrapericardial (IP) approach potentially achieves high concentrations of the therapeutic agent in the infarcted area. We aimed to evaluate IP therapy using a saline vehicle as a control (CON), a dose of 30 × 106 CDCs (CDCs) or APA microcapsules containing 30 × 106 CDCs (APA-CDCs) at 72 h in a porcine AMI model. Magnetic resonance imaging (MRI) was used to determine the left ventricular ejection fraction (LVEF), infarct size (IS), and indexed end diastolic and systolic volumes (EDVi; ESVi) pre-and 10 weeks post-injection. Programmed electrical stimulation (PES) was performed to test arrhythmia inducibility before euthanasia. Histopathological analysis was carried out afterwards. The IP infusion was successful in all animals. At 10 weeks, MRI revealed significantly higher LVEF in the APA-CDC group compared with CON. No significant differences were observed among groups in IS, EDVi, ESVi, PES and histopathological analyses. In conclusion, the IP injection of CDCs (microencapsulated or not) was feasible and safe 72 h post-AMI in the porcine model. Moreover, CDCs APA encapsulation could have a beneficial effect on cardiac function, reflected by a higher LVEF at 10 weeks. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000119591 536__ $$9info:eu-repo/grantAgreement/ES/AEI PID2019-107329RA-C22-AEI-10.13039-501100011033$$9info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe$$9info:eu-repo/grantAgreement/ES/ISCIII CB16-11-00494$$9info:eu-repo/grantAgreement/ES/ISCIII/CD19-00048$$9info:eu-repo/grantAgreement/ES/ISCIII/PI20-00247
000119591 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000119591 590__ $$a6.525$$b2021
000119591 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 279 = 0.14$$c2021$$dQ1$$eT1
000119591 592__ $$a0.922$$b2021
000119591 593__ $$aPharmaceutical Science$$c2021$$dQ1
000119591 594__ $$a6.0$$b2021
000119591 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119591 700__ $$aBlanco-Blázquez V.
000119591 700__ $$aSánchez-Margallo F.M.
000119591 700__ $$aLópez E.
000119591 700__ $$aMartín H.
000119591 700__ $$aEspona-Noguera A.
000119591 700__ $$aCasado J.G.
000119591 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza J.$$uUniversidad de Zaragoza
000119591 700__ $$aPedraz J.L.
000119591 700__ $$aCrisóstomo V.
000119591 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000119591 773__ $$g13, 11 (2021), 1824 [14 pp]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000119591 8564_ $$s2188377$$uhttps://zaguan.unizar.es/record/119591/files/texto_completo.pdf$$yVersión publicada
000119591 8564_ $$s2742916$$uhttps://zaguan.unizar.es/record/119591/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119591 909CO $$ooai:zaguan.unizar.es:119591$$particulos$$pdriver
000119591 951__ $$a2023-05-18-15:25:27
000119591 980__ $$aARTICLE